Literature DB >> 19148799

Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection.

Kazuhiko Koike1.   

Abstract

In addition to the link with development of hepatocellular carcinoma (HCC), hepatitis C virus (HCV) infection is associated with several hepatic and extrahepatic manifestations. A role of hepatic steatosis in the pathogenesis of chronic hepatitis C has been shown, implying hepatitis C as a metabolic disease. Furthermore, recent epidemiological studies have suggested a linkage between insulin resistance and chronic HCV infection. In addition to the data indicating the presence of lipid metabolism disturbance and insulin resistance in the cohort of chronic hepatitis C patients, we found evidence showing the association between these two conditions and HCV infection using mice transgenic for the HCV core gene. These mice develop HCC late in life after the phase of hepatic steatosis and insulin resistance. The nonappearance of both steatosis and HCC in HCV core gene transgenic mice that are null for the proteasome activator 28gamma implies a close relationship between lipid metabolism disturbance and hepatocarcinogenesis. Also, the core protein is shown to bind with retinoid X receptor (RXR)-alpha, resulting in the upregulation of some lipid metabolism enzymes, including cellular retinol binding protein II and acyl-CoA oxidase. In addition, the persistent activation of peroxisome proliferator activated receptor (PPAR)-alpha has recently been found in the liver of HCV core gene transgenic mice, yielding dramatic changes in lipid metabolism and hepatocyte proliferation, including HCC development. These results would provide a clue for further understanding of the role of lipid metabolism in pathogenesis of HCV infection, including liver injury and hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148799     DOI: 10.1007/s00535-008-2276-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

Review 1.  Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies.

Authors:  Kazuhiko Koike
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

2.  Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation.

Authors:  Keigo Machida; Kevin T-H Cheng; Chao-Kuen Lai; King-Song Jeng; Vicky M-H Sung; Michael M C Lai
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 3.  Does oxidative stress participate in the development of hepatocellular carcinoma?

Authors:  Yutaka Sasaki
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

4.  Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans.

Authors:  K Moriya; T Todoroki; T Tsutsumi; H Fujie; Y Shintani; H Miyoshi; K Ishibashi; T Takayama; M Makuuchi; K Watanabe; T Miyamura; S Kimura; K Koike
Journal:  Biochem Biophys Res Commun       Date:  2001-03       Impact factor: 3.575

5.  Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Takashi Shimoike; Ryosuke Suzuki; Kyoji Moriya; Yoshizumi Shintani; Hajime Fujie; Yoshiharu Matsuura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

6.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

7.  Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes.

Authors:  K Koike; K Moriya; K Ishibashi; H Yotsuyanagi; Y Shintani; H Fujie; K Kurokawa; Y Matsuura; T Miyamura
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

8.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors:  Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

9.  Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Kyoji Moriya; Yoshizumi Shintani; Hajime Fujie; Hideyuki Miyoshi; Yoshiharu Matsuura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

10.  Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Kyoji Moriya; Hiroshi Yotsuyanagi; Yoshizumi Shintani; Hajime Fujie; Yoshiharu Matsuura; Satoshi Kimura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

View more
  26 in total

1.  Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Authors:  María Trapero-Marugán; Jorge Mendoza; María Chaparro; Leticia González-Moreno; José Andrés Moreno-Monteagudo; María Jesús Borque; Ricardo Moreno-Otero
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

Review 3.  Hepatitis B virus infection in Indonesia.

Authors:  Yoshihiko Yano; Takako Utsumi; Maria Inge Lusida; Yoshitake Hayashi
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 4.  Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma.

Authors:  Tohru Utsunomiya; Mitsuo Shimada; Satoru Imura; Yuji Morine; Tetsuya Ikemoto; Masaki Mori
Journal:  J Gastroenterol       Date:  2009-12-08       Impact factor: 7.527

5.  Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.

Authors:  Xiufang Weng; Ying He; Lavanya Visvabharathy; Chia-Min Liao; Xiaosheng Tan; Arjun Balakumar; Chyung-Ru Wang
Journal:  J Hepatol       Date:  2017-07-14       Impact factor: 25.083

6.  Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients.

Authors:  Takumi Akiyama; Toshihiko Mizuta; Seiji Kawazoe; Yuichiro Eguchi; Yasunori Kawaguchi; Hirokazu Takahashi; Iwata Ozaki; Kazuma Fujimoto
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

7.  Peroxisome proliferator-activated receptors and hepatitis C virus.

Authors:  M Eslam; M A Khattab; S A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

8.  Role of Hepatitis C virus core protein in viral-induced mitochondrial dysfunction.

Authors:  T Wang; R V Campbell; M K Yi; S M Lemon; S A Weinman
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

9.  The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Shuji Kanmura; Hirofumi Uto; Yuko Sato; Koutarou Kumagai; Fumisato Sasaki; Akihiro Moriuchi; Makoto Oketani; Akio Ido; Kenji Nagata; Katsuhiro Hayashi; Sherri O Stuver; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-12-09       Impact factor: 7.527

Review 10.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.